MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
But the Astra/Daiichi ADC stumbles in lung cancer.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company quietly deprioritises AlphaMedix.
The company is starting four new pivotal trials this year.
